



**HAL**  
open science

## Vitamin D and Obesity/Adiposity-A Brief Overview of Recent Studies

Imene Bennour, Nicole Haroun, Flavie Sicard, Lourdes Mounien,  
Jean-François Landrier

► **To cite this version:**

Imene Bennour, Nicole Haroun, Flavie Sicard, Lourdes Mounien, Jean-François Landrier. Vitamin D and Obesity/Adiposity-A Brief Overview of Recent Studies. *Nutrients*, 2022, 14 (10), pp.1-16. 10.3390/nu14102049 . hal-03777049

**HAL Id: hal-03777049**

**<https://hal.inrae.fr/hal-03777049>**

Submitted on 14 Sep 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution| 4.0 International License

Review

# Vitamin D and Obesity/Adiposity—A Brief Overview of Recent Studies

Imene Bennour<sup>1,†</sup>, Nicole Haroun<sup>1,†</sup>, Flavie Sicard<sup>1,2</sup>, Lourdes Mounien<sup>1,2</sup>  and Jean-François Landrier<sup>1,2,\*</sup> 

- <sup>1</sup> Aix-Marseille Université, C2VN, INRAE, INSERM, 13000 Marseille, France; imene.bennour@univ-amu.fr (I.B.); nicole.haroun@univ-amu.fr (N.H.); flavie.sicard@univ-amu.fr (F.S.); lourdes.mounien@univ-amu.fr (L.M.)
- <sup>2</sup> PhenoMARS Aix-Marseille Technology Platform, CriBiom, 13000 Marseille, France
- \* Correspondence: jean-francois.landrier@univ-amu.fr; Tel.: +33-4-9129-4275
- † These authors contributed equally to this work.

**Abstract:** Observational studies classically find an inverse relationship between human plasma 25-hydroxyvitamin D concentration and obesity. However, interventional and genetic studies have failed to provide clear conclusions on the causal effect of vitamin D on obesity/adiposity. Likewise, vitamin D supplementation in obese rodents has mostly failed to improve obesity parameters, whereas several lines of evidence in rodents and prospective studies in humans point to a preventive effect of vitamin D supplementation on the onset of obesity. Recent studies investigating the impact of maternal vitamin D deficiency in women and in rodent models on adipose tissue biology programming in offspring further support a preventive metabolically driven effect of vitamin D sufficiency. The aim of this review is to summarize the state of the knowledge on the relationship between vitamin D and obesity/adiposity in humans and in rodents and the impact of maternal vitamin D deficiency on the metabolic trajectory of the offspring.

**Keywords:** preventive nutrition; maternal programming; micronutrients; obesity



**Citation:** Bennour, I.; Haroun, N.; Sicard, F.; Mounien, L.; Landrier, J.-F. Vitamin D and Obesity/Adiposity—A Brief Overview of Recent Studies. *Nutrients* **2022**, *14*, 2049. <https://doi.org/10.3390/nu14102049>

Academic Editor: Luigi Barrea

Received: 15 March 2022

Accepted: 11 May 2022

Published: 13 May 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Vitamin D (VD, here used as a generic term) has a well-established role in the maintenance of phosphate and calcium homeostasis and a clearly essential function in bone and muscle health [1]. For some years now, VD has attracted increasing attention due to the resurgence of VD deficiency in children and adults worldwide [2–4] and its suspected multiple extraskeletal benefits, including for cardiometabolic health [1,5]. In the cardiometabolic context, a huge number of in vitro experiments have clearly mapped out the actions of vitamin D on key parameters of adipose tissue and adipocyte biology including adipogenesis and the regulation of gene expression in response to energy homeostasis and inflammation (see [6–8] for reviews). These lines of evidence all converge towards a beneficial role of vitamin D in the physiology of adipose tissue, prompting a massive body of research attempting to unravel the relationship between vitamin D and obesity/adiposity in humans and in animals. This review set out to summarize the state of knowledge on this VD–obesity/adiposity relationship and point towards its grey areas and its more robust conclusions.

## 2. Sources and Absorption of Vitamin D

Vitamin D is unique in that it can be both sourced by food and produced endogenously, which means that it has the properties of both a vitamin and a hormone. VD is mainly produced in skin exposed to UVB light, which converts 7-dehydrocholesterol to pre-vitamin D<sub>3</sub>, which is then further isomerized to vitamin D<sub>3</sub> by the action of heat before being released into the circulation [9], where it binds to vitamin D-binding protein (VDBP). The real contribution of endogenous VD production is still under debate: some papers

assert that endogenous VD synthesis accounts for up to 70–90% of VD supply whereas others suggest it is just 10–25% of VD supply [10]. The amount of vitamin D<sub>3</sub> that is endogenously produced remains highly variable and depends on several factors including latitude, pollution, season, use of sunscreen, clothing, sedentary lifestyle, skin color, and age, among others [11].

Natural exogenous sources of VD are relatively scarce. VD is found in animal-source products (mainly fish liver oil, fatty fish such as salmon, sardines, herring and mackerel, and egg yolk) providing vitamin D<sub>3</sub> or ‘cholecalciferol’ [12,13]. Plants and mushrooms are sources of vitamin D<sub>2</sub> or ‘ergocalciferol’. Vitamin D (mainly as D<sub>3</sub>) can also be added in small amounts in fortified milk, margarine or butter, orange juice, and bread or cereals.

After ingestion and emulsion with bile acids [14,15], dietary VD is absorbed in the median part of the small intestine [16]. This process, initially assumed to be passive [17], also requires three apical membrane transporters: Scavenger receptor class B type I (SR-BI), Cluster of differentiation 36 (CD36) and Niemann–Pick C1-like 1 protein (NPC1L1) [18]. A part of the absorbed VD is effluxed by enterocytes via ATP-binding cassette subfamily B member 1 (ABCB1) [19]. The intracellular transport of VD in enterocytes remains unclear, but it ultimately is incorporated in chylomicrons to be secreted in the lymph and delivered to the liver and/or storage organs.

### 3. Metabolism of the Vitamin D

#### 3.1. Hydroxylation of Vitamin D and Metabolites

In the liver, endogenous or dietary VD is enzymatically hydroxylated to 25-hydroxyvitamin D (calcifediol, 25(OH)D) (Figure 1). This reaction is catalyzed by microsomal cytochrome P450 enzyme CYP2R1, which is considered the key enzyme of 25 hydroxylation [20–22]. However, several other enzymes display a 25-hydroxylation activity on VD, including CYP27A1, CYP2C11, CYP3A4, and CYP2J2 in humans [23–25].




Figure 1. Vitamin D metabolism.

Although the 25-hydroxylation is classically thought to be poorly regulated, Bell et al. reported that hepatic 25-hydroxylation was inhibited by 1,25(OH)<sub>2</sub>D and parathyroid hormone (PTH) in humans [26]. Furthermore, several recent studies have described the inhibition of *Cyp2r1* mRNA levels and/or 25-hydroxylation activity in the liver of

obese/diabetic mice [27–31] via mechanisms involving several transcription factors including PGC1 $\alpha$  and GR [31]. The 25(OH)D thus produced is the major circulating form of VD, with a half-life of about 15 days, and is classically used as a biomarker of VD status [32]. Circulating 25(OH)D is bound to VDBP [33], a serum  $\alpha$ 2-globulin encoded by the *Gc* gene and synthesized by the liver that is considered as the major plasma protein carrier of VD and its metabolites [34,35]. Indeed, around 80% of plasma 25(OH)D is bound to VDBP, while 19% of 25(OH)D is linked to albumin and the remainder is a free fraction that is thought to be biologically active [36]. The fact that VDBP-null mice remained normal under a VD-sufficient diet suggests that free 25(OH)D levels cover body requirements for physiological functions [37].

The VDBP-bound 25(OH)D is then transported to the kidneys and various other organs and tissues, where it is used for 1 $\alpha$ -hydroxylation. In renal proximal tubule cells, the VDBP–25(OH)D complex enters by endocytosis and thus escapes urinary loss [38,39]. This step requires the presence of megalin and cubilin [40]. Cubilin is responsible for sequestration of the VDBP–25(OH)D complex before internalization by megalin. After internalization into vesicles, the VDBP is degraded by lysosomes and the 25(OH)D is handled by intracellular VDBP [41]. The 25(OH)D is then either secreted into circulation or delivered to mitochondria to be metabolized into 1,25(OH)<sub>2</sub>D, the biologically active form of VD. This reaction is catalyzed by 1 $\alpha$ -hydroxylase CYP27B1 and stimulated by PTH and low calcium and phosphorus concentrations, inhibited by FGF23, and self-regulated by 1,25(OH)<sub>2</sub>D via a negative feedback mechanism [42].

VD metabolism is ultimately self-regulated via an inactivation pathway that involves CYP24A1-mediated 24-hydroxylation leading to the conversion of 25(OH)D and 1,25(OH)<sub>2</sub>D into 24,25(OH)D and 1,24,25(OH)<sub>3</sub>D, catabolized into inactive calcitroic acid [43]. This inactivation is induced by 1,25(OH)<sub>2</sub>D itself via an induction of CYP24A1.

### 3.2. Mechanisms of Action of Vitamin D

The nuclear receptor-family vitamin D receptor (VDR) is known to mediate the bulk of the biological effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> [44]. Its ubiquitous distribution explains why a large number of genes (more than 1000) are either directly or indirectly regulated by 1,25(OH)<sub>2</sub>D [44]. VDR heterodimerizes with retinoid X receptor (RXR) and binds to DNA at sites called vitamin D response elements (VDRE) that are located in the promoter regions of VD-regulated genes. In the absence of a ligand, this heterodimer complexes with co-repressors and histone deacetylases, whereas in the presence of 1,25(OH)<sub>2</sub>D, it recruits co-activators and histone acetyltransferases, leading to transcriptional activation [45]. This genomic effect of VD through VDR is strongly suspected to drive a large share of the biological effects of VD in health and disease, notably in the context of obesity, based on evidence from several studies that point to a correlation between VDR polymorphism and pathological issues [46].

The non-genomic effects of VD are characterized by very fast (seconds to minutes) activation of signaling pathways involving phospholipases C and A2, phosphoinositide 3-kinase, protein kinase A, and mitogen-activated protein kinases. It also includes the opening of Ca<sup>2+</sup> and Cl<sup>−</sup> channels. These non-genomic effects of VD are dependent on protein disulfide isomerase family A member3 (PDIA3, also known as ERp57, GRP58 and 1,25-MARRS) [47,48], a membrane receptor found in enterocytes, osteoblasts and hepatocytes [49–51].

Several epigenetic effects of VD have been described in a number of models and pathophysiological contexts. These effects include DNA methylation, possibly through modulation of DNA methyltransferase and/or DNA demethylase expression [52]. VD can also regulate histone acetylation via activation of histone acetyltransferases and histone deacetylases, but also histone methylation and demethylation, thus modulating chromatin accessibility to transcription factors [53]. Finally, VD is also reported to play a role in regulating the expression of some micro-RNAs (miRNAs) [53], and we recently published

data showing that 1,25(OH)<sub>2</sub>D downregulates inflammation-related miRNAs expression in adipocytes both in vitro and in vivo [54].

#### 4. Relationship between Obesity and Vitamin D in Rodents

The decrease in plasma 25(OH)D concentrations with obesity is clear in humans, but is less clear in mice (Table 1). Indeed, the decrease in total 25(OH)D is not always obvious, since authors report no modification of 25(OH)D plasma concentration [28,29,55–58], whereas other studies depict a decrease [27,59–61]. The origin of these divergences in mouse studies is still unclear, but could be due to the composition of the high-fat (HF) diet used to induce obesity and/or the methods used to quantify 25(OH)D, i.e., immunoassay tests vs. mass spectrometry. For instance, we initially reported a decrease in 25(OH)D plasma concentrations under HF diet based on ELISA quantification [60], but recent protocols, performed with the same type of diet but using mass spectrometry analysis for 25(OH)D quantification, found no such decrease [29,55].

**Table 1.** Relationship between VD and obesity in rodents.

	In Rodents	References
25(OH)D plasma levels	Lack of clear-cut results (decrease or no effect reported)	[27–29,55–61]
Free 25(OH)D plasma levels	Reduced in obese mice	[29,55]
1,25(OH) <sub>2</sub> D plasma levels	Lack of clear-cut results (increase, decrease or no effect reported)	[28,29,55,56,59]
VDR <sup>-/-</sup> mice	Reduced obesity/adiposity	[62–66]
Adipose tissue human VDR overexpression	Increase obesity/adiposity	[66,67]
Adipose tissue VDR <sup>-/-</sup> mice	Increase obesity/adiposity	[68,69]
	No effect on obesity/adiposity	[70]
Curative effect of VD supplementation on obesity	No	[58,71]
Curative effect of 1,25(OH) <sub>2</sub> D supplementation on obesity	Yes	[72]
Preventive effect of VD supplementation on obesity	Reduction of obesity/adiposity	[60,73–76]
	No effect on obesity/adiposity	[56,57,59,61,77–79]
	Decrease in obesity/adiposity	[80–82]
Effect of VD supplementation on 25(OH)D plasma levels in obese rodents	Increase 25(OH) plasma levels	[58–60,83,84]
	No effect	[56,57]

VDR: vitamin D receptor; VD: vitamin D; 25(OH)D: 25-hydroxyvitamin D; 1,25(OH)<sub>2</sub>D: 1,25-dihydroxyvitamin D.

Other VD metabolites have been measured in obese rodents. We recently reported lower free 25(OH)D rates in obese mice [29,55], which is in agreement with human data [85]. Studies investigating the relationship between obesity and plasma 1,25(OH)<sub>2</sub>D concentrations in mice have found no clear pattern, as some report decreased plasma 1,25(OH)<sub>2</sub>D [56,59] whereas others find no change [55] and others even find increased plasma 1,25(OH)<sub>2</sub>D [28,29]. The pattern probably depends on composition of the HF diet and/or duration of the diet administration.

As is the case in humans, several rodent studies using wild-type or transgenic mice models have attempted to elucidate the impact of diet supplementation with cholecalciferol or active metabolites of VD on obesity. VDR<sup>-/-</sup> mice were studied to gain insight into the role of VD metabolism on body weight management and adipose tissue biology [62–66]. These mice remain lean and resistant to diet-induced obesity, probably due to the induction of fatty acid oxidation and uncoupling proteins (including UCP1, 2 and 3) in adipose



tissue leading to increased energy expenditure. Even if these data strongly suggest that VDR deletion improves energy homeostasis, there are several caveats: the mice were fed a rescue diet containing large amounts of calcium, which is suspected to regulate energy homeostasis [86]; the VDR gene was ablated from the entire mouse, making it impossible to attribute the overall phenotype to a specific tissue [42,68]; VDR<sup>-/-</sup> mice develop alopecia, and the resulting reduced insulation could increase energy expenditure to maintain body temperature [87].

Other studies have using targeted overexpression or invalidation of VDR in adipose tissue. The overexpression of human VDR in mouse adipose tissue induced an increase in weight and fat pad mass associated with a decrease in energy expenditure and fatty acid oxidation [66,67]. Conversely, adipose tissue-specific invalidation of VDR (Cre recombinase under control of the FABP4 promoter) increased visceral fat pad weight compared to wild-type mice in females only [68] but had no effect on adiposity and body weight in another model (Cre recombinase under control of the adiponectin promoter) [70]. Interestingly, a recent article also reported that adipocyte-specific VDR ablation (Cre recombinase under control of the mouse adiponectin promoter) led to a slight increase in weight gain and an increase in visceral white adipose tissue [69]. Taken together, these observations still give no clear picture of the specific role of VDR in adipose tissue biology and weight management. Furthermore, they also point to a sex-specific effect of VDR that warrants further investigation.

Few studies have been conducted in rodents to evaluate the value or benefit of VD supplementation as a curative strategy. We recently tested VD supplementation in obese mice and found that despite several phenotypical improvements, notably in terms of adipose tissue inflammation, hepatic steatosis and cardiac function, there was no observable improvement in body weight or adiposity [58,74,75], which is in agreement with another study [71]. However, obese mice subjected to 1,25(OH)<sub>2</sub>D injections showed improved body weight and adiposity [72], suggesting that 1,25(OH)<sub>2</sub>D could be more efficient than VD, probably due to the effect of obesity on VD metabolism.

The effect of VD or its metabolites has been more amply described as a preventive strategy against obesity. Several studies have reported a reduction in body weight and/or adiposity in rodents under VD [60,73–75] or 1,25(OH)<sub>2</sub>D supplementation [76]. Additionally, it should be noted that VD insufficiency exacerbated adiposity and body weight gain [88–90]. The molecular mechanisms are not fully elucidated but may involve an action of VD in the induction of lipid catabolism, notably in the liver and in brown adipose tissue [60]. Interestingly, the ability of 1,25(OH)<sub>2</sub>D to reduce adiposity and induce lipid oxidation in adipose tissue has been confirmed in a *cyp2r1*-deficient zebrafish model [91,92].

Conversely, some studies have reported no effect of VD supplementation or VD deficiency on body weight, adiposity, or adipose tissue fat pad mass [56,57,59,61,77–79], whereas other studies reported that VD deficiency decreased HF diet-induced obesity in rodents [80–82]. The lack of clear-cut results is problematic, and the origin of these discrepancies remains partly unexplained. Of course, several key parameters are highly variable between studies and could explain the divergent results. Among them are the different quantities of dietary and/or supplemented VD, the quantity and type of lipids incorporated in the HF regimen used, the duration of the regimen and supplementation, and the age of the animals at the beginning of the supplementation are regularly cited, but would require a deeper investigation. Another important issue is the lack of reproducible effect of VD supplementation on plasma 25(OH)D, especially against a background of obesity. Indeed, some authors reported an increase in plasma 25(OH)D [58–60,83,84], whereas others reported no effect under VD supplementation [56,57]. It is, therefore, conceivable that the lack of effect of VD on obesity parameters coincides with an absence of detectable increase in 25(OH)D. Note that the difference in concentrations of VD used for supplementation could partly explain these discrepancies, but is clearly not the sole factor. Diet composition and level of 25(OH)D at baseline could also play a major role, as recently highlighted in the case of Mediterranean diet [93], but further research is needed.

## 5. Relationship between VD and Obesity in Human Observational Studies

A large set of cross-sectional studies recently reviewed in deep [94,95] have pointed out the inverse relationship between low serum 25(OH)D and obesity [96] (Table 2). Indeed, it is assumed that plasma 25(OH)D is inversely correlated with most parameters of obesity, such as body mass index (BMI), total fat mass, subcutaneous and visceral adiposity, and waist circumference [97]. These observations have been found in adults but also in children [98] and in aging people [99]. Furthermore, a recent study found that free plasma 25(OH)D and 1,25(OH)<sub>2</sub>D level are lower in obese subjects than normal-weight subjects (85), as also suggested elsewhere [100,101]. This could be due to the reduced release of 1,25(OH)<sub>2</sub>D from subcutaneous adipose tissue under the isoprenaline-mediated lipolysis that occurs during obesity [102].

Many hypotheses have been put forward to explain the low levels of 25(OH)D (total and/or free) associated with obesity. Differences in lifestyle patterns between people with or without obesity cannot be ruled out, including dietary habits, sedentary lifestyle or clothing habits, and there may also be reduced hepatic synthesis of 25(OH)D due to obesity-associated secondary hyperparathyroidism [26], but the key mechanism appears to be VD sequestration. Indeed, the excess adipose tissue observed during obesity could offer an extended storage site for VD and/or 25(OH)D, leading to low plasma 25(OH)D concentrations [103], but this assumption was challenged by Drincic et al. who reported that 25(OH)D was simply diluted in a higher volume in people with obesity, in line with the volumetric dilution hypothesis [104]. Alternative hypotheses have been put forward that suggest modifications in VD metabolism, notably in adipose tissue, where *CYP2J2* mRNA levels were found to be lower in obese women compared to lean women [105]. A recent review argued for a similar set of possible factors affecting vitamin D levels in aging people with obesity (i.e., sequestration or dilution of VD in adipose tissue, increased catabolism of VD in adipose tissue, reduced 25-hydroxylation and reduced sun exposure) [99].

In accordance with the hypothesis of VD sequestration in adipose tissue, a recent meta-analysis highlighted that obesity reduces the effect of VD supplementation in patients with obesity [106]: serum VD concentrations were found to be  $-38.17$  nmol/L lower in obese subjects compared to the normal-weight group, and increasing VD doses did not significantly increase 25(OH)D plasma concentrations, underlining the urgent need to develop strategies for optimal VD supplementation for people with obesity.

Prospective studies suggest that low plasma 25(OH)D levels are associated with a strong prevalence of obesity in children [107], adults [108,109], and elderly women [110], and low VD intake may predict later obesity and metabolic syndrome [111] and even onset of obesity [112].

Some studies have found relationships between VDR polymorphisms and BMI, adiposity markers, or obesity [113–116] and other research has found a relationship between BMI and polymorphisms of VDBP and *CYP27b1* [117]. However, larger studies failed to demonstrate correlations between polymorphisms in genes coding for key drivers of VD metabolism [118,119]. Interestingly, it has been reported that polymorphisms in VDR may influence changes in visceral fat and waist circumference in people supplemented with VD [46]. Mendelian randomization analysis using genes involved in VD metabolism as instrumental variables (VDBP, *DHCR7*, *CYP2R1* and *CYP24A1*) suggested that low 25(OH)D has little or no impact on BMI [120], that obesity promoted the reduction in plasma 25(OH)D and that a 1 kg increase in body weight leads to a 1.15% decrease in 25(OH)D. Consistently with these findings, a systemic review and meta-analysis of randomized and non-randomized controlled trials showed that weight loss can improve plasma 25(OH)D concentrations [121], and another meta-analysis reported that a weight loss of approximately 10 kg without VD supplementation could increase plasma 25(OH)D concentration by up to 6 nmol/L [122].

## 6. Relationship between VD and Obesity in Human Interventional Studies

Several randomized clinical trials (RCT) have been implemented and recently meta-analyzed in an effort to establish the causal link between low plasma VD levels and obesity (Table 2). Results contrasted between each RCT depending on experimental design (population recruited, 25(OH)D at baseline, duration of VD supplementation, VD dose, etc.). Two meta-analyses failed to show a beneficial effect of VD supplementation on measures of obesity (BMI, fat mass, percentage of fat mass or lean body mass) [123,124] whereas a third meta-analysis pointed to improved BMI and waist circumference following VD supplementation [125]. This lack of clear-cut results is unfortunately common in RCT testing the therapeutic effect of VD, and Dr. BJ Boucher recently highlighted several highly pertinent ways to address this issue by improving RCT design and analysis to obtain definite answers on whether effects of VD translate into real health benefits [126].

**Table 2.** Relationship between VD and obesity in humans.

	In Humans	References
25(OH)D plasma levels	Reduced in obesity, inversely correlated to markers of obesity and adiposity	[94–99]
Free 25(OH)D plasma levels	Reduced in obesity	[85]
1,25(OH) <sub>2</sub> D plasma levels	Reduced in obesity	[100,101]
Impact of obesity on VD supplementation	Obesity reduced the efficacy of VD supplementation	[106]
Low 25(OH)D predictor for obesity onset (Prospective studies)	Yes	[107–112]
Effect of polymorphisms in genes coding for proteins involved in VD metabolism (Genetic studies)	Relationship between obesity and SNP in VDR, VDBP, and Cyp27b1 in small cohorts No link between polymorphisms and obesity in larger cohorts	[113–117] [118,119]
Causal effect of low 25(OH)D on obesity (Mendelian randomization)	No	[120]
Causal effect of obesity on low 25(OH)D (Mendelian randomization)	Yes	[120]
Weight lost increase 25(OH)D plasma levels	Yes	[121]
Impact of VD supplementation on obesity (RCT)	Lack of clear-cut results (2 meta-analysis showing no effect, 1 meta-analysis showing improvement of obesity parameters following VD supplementation)	[123–125]

VD: vitamin D; 25(OH)D: 25-hydroxyvitamin D; 1,25(OH)<sub>2</sub>D: 1,25-dihydroxyvitamin D; SNP: single nucleotide polymorphisms.

## 7. Maternal Vitamin D Deficiency and Links to Obesity and Adipose Tissue Biology

Investigations are starting to unravel the role of VD during pregnancy [127–130]. Adequate VD intake during pregnancy is essential for both maternal and fetal health. Indeed, epidemiological studies describe a large range of adverse maternal, fetal and neonatal outcomes associated with VD deficiency [131], such as increased risk for preeclampsia [132], gestational diabetes mellitus [133], higher risk of small-for-gestational-age at term and reduced-term birth weight, and lower head circumference [134–137].



### *7.1. Lines of Epidemiological and Clinical Evidence for a Link between VD and Obesity in Offspring*

Recent studies on large mother–child cohorts have suggested associations between maternal plasma 25(OH)D content and various parameters characterizing obesity in children. In a cohort of 977 pregnant women, low 25(OH)D concentration at 34 weeks of pregnancy was associated with low percent fat mass at birth and high percent fat mass in children aged 4 and 6 [138]. Similar results were observed in a cohort of 922 mother–child pairs where increased maternal 25(OH)D plasma levels at 15 weeks of pregnancy was associated with decreased percent body fat in offspring [139]. In another cohort including 4903 mothers and their children, severe maternal 25(OH)D deficiency during pregnancy was associated with higher percent fat mass and lower percent lean body mass in children at 6 years [140]. In a cohort of 568 mother–child pairs, boys but not girls born to mothers with 25(OH)D deficiency had higher percent fat mass and lower percent fat-free mass at 5 years of age [141]. In a smaller cohort (292 mother–neonate pairs, low maternal 25(OH)D levels were associated with greater superficial and deep abdominal subcutaneous adipose tissue volume in neonates [142]. Other studies in humans have found that maternal VD status is associated with BMI, weight and waist circumference in offspring. Indeed, 25(OH)D concentrations during pregnancy were inversely correlated with BMI and waist circumference in children aged 4 and 6 years [143] but also with high risk for fetal and neonatal overweight [144].

Convergent evidence from all these epidemiological studies therefore tends to confirm the role of maternal VD status in developmental programming of obesity in the offspring. However, long-term studies (follow-up to adulthood) remain scarce; the only study with long-term follow-up (20 years) found no association between maternal VD status and cardiometabolic risk factors [145], and the early mechanisms involved in this programming remain to be elucidated.

RCTs to evaluate the effect of VD supplementation during pregnancy have been conducted and recently meta-analyzed (3725 participants from 22 trials) [146]. Supplementation with VD during pregnancy probably reduced the risks for preeclampsia, gestational diabetes, and babies with low birth weight at term. Another recent meta-analysis (3960 participants from 11 RCTs) found that VD supplementation was also associated with lower BMI and BMI z-score in children aged 3–6 years [147]. However, these data remain weak and the certainty level is only moderate, and so further large RCTs are needed to confirm these results.

### *7.2. Lines of Preclinical Evidence for a Link between VD and Obesity in Offspring*

A study conducted in rats showed that maternal VD deficiency induced before and during gestation appears to promote adipocyte and preadipocyte differentiation and proliferation in VD-deficient male offspring [148]. This phenomenon seems to be associated with epigenetic changes (differential methylation of promoters and CpG islets) leading to an obese phenotype (increased body mass and adiposity) in the offspring from VD-deficient females [148]. In mice, maternal VD deficiency is also associated with an obese phenotype in male offspring characterized by higher body mass, adiposity and glucose intolerance but did not translate over to a second generation [149]. Another study also reported glucose intolerance and slower growth in mice born from VD-deficient dam [136].

In a transgenerational study, maternal VD deficiency induced by a VD-deficient diet (from 5 weeks before mating until weaning) lead to disturbances in DNA methylation in somatic liver and germ cells (sperm) over two successive generations. These epigenetic changes were associated with differences in body weight and lean mass-to-fat mass ratio over the two generations [150].

However, this association between maternal VD deficiency and obese phenotype in the offspring is not systematically observed. A study of male Sprague Dawley rats from dams deficient in VD during gestation found no difference in body mass [151], but the offspring showed insulin resistance (high HOMA-IR and lowered glucose tolerance) associated with

persistent inflammation (with high plasma and liver levels of IL-1 $\beta$ , IL-6, IL-8 and TNF $\alpha$ ). Interestingly, the persistently increased inflammation was explained by the continuously increased I $\kappa$ B $\alpha$  expression related to methylation modifications [151]. Likewise, male mice from VD-deficient dams with intrauterine growth retardation and accelerated growth early in life did not have a higher mass in adulthood [152]. Nevertheless, these animals were predisposed to develop adipocyte hypertrophy in response to a high-fat diet.

We recently reported that juvenile males born to VDD dams had lower body weight and higher energy expenditure compared with controls, whereas females showed no change in body weight [153], which, for the first time, highlights a strong sex-specific metabolic response. Furthermore, we showed that challenging offspring with a HF diet strongly increased adiposity index and insulin resistance in males born to VDD mice, which correlated with insulin resistance, whereas the HF diet-challenged females born to VDD mice had a similar adiposity index and insulin sensitivity to control-diet females. These phenotypes (adiposity and insulin sensitivity) were associated with different transcriptomic profiles in white adipose tissue, prompting us to posit that the specific phenotypic response in females was linked to 17 $\beta$ -estradiol concentrations increased by maternal VD deficiency.

Taken together, these observations support a detrimental role of VD deficiency in terms of mediation of obesity and adiposity that appears to be sex-dependent and also appears to be further exacerbated by HF diet in rodents. However, the molecular mechanisms mediating this phenotype remain elusive.

## 8. Conclusions and Perspectives

The past decade of research has generated very interesting data in transgenic mice and rodents subjected to vitamin D supplementation or restriction, but still without convergent findings. It is vital to pinpoint the origin of these discrepancies, but also to keep in mind that VD deficiency during adulthood is totally different from global embryonic invalidation of the VDR (due to VDR ligand-independent activities and non-genomic effects of VD, among other factors).

Curative approaches based on VD supplementation have recently been implemented in mice but failed to improve obesity or adiposity. Similar results have been found in RCTs on supplementation to patients with obesity, which have mostly failed to confirm a beneficial role of VD supplementation on weight management. Several points for improvement are regularly proposed and should obviously be applied in future RCT designs, in line with Heaney's guidelines [154]. Trial designs would ideally always include people with measured baseline 25(OH)D and possibly 25(OH)D deficiency in order to highlight benefits of VD supplementation benefit, but these would be ethical issues to address. It would also require supplementing subjects with substantial doses of VD in order to observe a large change in VD status (not just VD intake). Co-nutrient status should also be optimized to limit risks of confounding factors in the biological response.

Even if the curative role of VD supplementation remains to be established, its preventive role is supported by prospective studies that converge to define low plasma 25(OH)D levels as a predictor of body weight gain. Rodent supplementation studies also partly support the preventive role of VD supplementation in obesity and adiposity. Some studies have nevertheless failed to demonstrate the preventive effect, which makes it vital to understand where such divergence comes from. The inconsistent findings could be linked, at least in part, to an inconsistent ability of VD supplementation to increase plasma 25(OH)D in mice models. Note that this preventive effect of VD is also supported by observational studies describing the impact of vitamin D deficiency in pregnant women on the metabolic programming of their offspring, which are supportive of a preventive metabolic effect of vitamin D sufficiency. Rodent models recently implemented will enable deeper exploration of the metabolic phenotype of offspring from VD-deficient female mice, and raise prospects for unravelling the molecular and epigenetic mechanisms involved in metabolic programming.

To conclude, several lines of evidence are supportive of a preventive effect of VD adequacy on obesity/adiposity, but a potential therapeutic role of VD supplementation for obesity and adiposity remains uncertain. In clinical practice, it is clearly necessary to keep 25(OH)D status within the normal range to avoid potentially associated risks in terms of obesity and adiposity. Well-designed clinical studies and fundamental research are urgently needed to confirm these assumptions.

VD exists in two forms: vitamin D<sub>3</sub>, which is produced in the skin and found in food, and vitamin D<sub>2</sub>, which is produced by plants and mushrooms. In the skin, 7-dehydrocholesterol is converted to cholecalciferol following sun exposure. Once synthesized, VD is transported into the circulation bound to VDBP or albumin, whereas dietary VD is absorbed in the median part of the small intestine in a process that requires apical membrane receptors (SR-B1, NPC1-L1, CD36), and is then transported into the circulation incorporated in chylomicrons. For VD to be biologically activated, it needs to undergo two hydroxylations. The first one takes place in the liver, and is catalyzed by enzymes that display 25-hydroxylation (CYP27A1, CYP2R1, CYP3A4, CYP2J2) activity. This reaction results in the formation of 25(OH)D which is then transported into the circulation in its free form, and bound to VDBP or to albumin. The second hydroxylation is performed in the kidney and is catalyzed by 1 $\alpha$ -hydroxylase CYP27B1, leading to the formation of 1,25(OH)<sub>2</sub>D. VD metabolism can be regulated: 25-hydroxylation is inhibited by 1,25(OH)<sub>2</sub>D concentration and PTH, and 1 $\alpha$ -hydroxylation is stimulated by PTH but inhibited by FGF23, calcemia, and 1,25(OH)<sub>2</sub>D via a negative feedback mechanism. Furthermore, VD metabolism is also self-regulated via an inactivation pathway that involves a CYP24A1-mediated 24-hydroxylation, leading to the conversion of 25(OH)D and 1,25(OH)<sub>2</sub>D into 24,25(OH)D and 1,24,25(OH)<sub>3</sub>D which is catabolized into inactive calcitroic acid.

1,25(OH)<sub>2</sub>D ultimately has many effects, including: (1) genomic effect that requires VDR and RXR and results in regulation of gene expression; (2) non-genomic effects via its association to the receptor 1,25-MARRS and subsequent activation of signaling pathways such as phospholipase C and phospholipase A<sub>2</sub>, phosphoinositide 3-kinase, protein kinase A, and mitogen-activated protein kinases; (3) epigenetic effects, including miRNA regulation, modulation of DNA methylation, histone acetylation/deacetylation and histone methylation/demethylation.

**Author Contributions:** Writing—original draft preparation, I.B. and N.H.; writing—review and editing, F.S., L.M. and J.-F.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work has been granted by INRAE, INSERM and AMU.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Christakos, S.; Dhawan, P.; Verstuyf, A.; Verlinden, L.; Carmeliet, G. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. *Physiol. Rev.* **2016**, *96*, 365–408. [[CrossRef](#)] [[PubMed](#)]
2. Holick, M.F. High prevalence of vitamin D inadequacy and implications for health. *Mayo Clin. Proc.* **2006**, *81*, 353–373. [[CrossRef](#)] [[PubMed](#)]
3. Holick, M.F. Vitamin D deficiency in 2010: Health benefits of vitamin D and sunlight: A D-bate. *Nat. Rev. Endocrinol.* **2011**, *7*, 73–75. [[CrossRef](#)] [[PubMed](#)]
4. Cashman, K.D.; Dowling, K.G.; Skrabakova, Z.; Gonzalez-Gross, M.; Valtuena, J.; De Henauw, S.; Moreno, L.; Damsgaard, C.T.; Michaelsen, K.F.; Molgaard, C.; et al. Vitamin D deficiency in Europe: Pandemic? *Am. J. Clin. Nutr.* **2016**, *103*, 1033–1044. [[CrossRef](#)]
5. de la Guía-Galipienso, F.; Martínez-Ferran, M.; Vallecillo, N.; Lavie, C.J.; Sanchis-Gomar, F.; Pareja-Galeano, H. Vitamin D and cardiovascular health. *Clin. Nutr.* **2021**, *40*, 2946–2957. [[CrossRef](#)]
6. Szymczak-Pajor, I.; Miazek, K.; Selmi, A.; Balcerczyk, A.; Sliwinska, A. The Action of Vitamin D in Adipose Tissue: Is There the Link between Vitamin D Deficiency and Adipose Tissue-Related Metabolic Disorders? *Int. J. Mol. Sci.* **2022**, *23*, 956. [[CrossRef](#)] [[PubMed](#)]
7. Park, C.Y.; Han, S.N. The Role of Vitamin D in Adipose Tissue Biology: Adipocyte Differentiation, Energy Metabolism, and Inflammation. *J. Lipid Atheroscler.* **2021**, *10*, 130–144. [[CrossRef](#)]

8. Nimitphong, H.; Park, E.; Lee, M.-J. Vitamin D regulation of adipogenesis and adipose tissue functions. *Nutr. Res. Pract.* **2020**, *14*, 553–567. [[CrossRef](#)]
9. Holick, M.F. Vitamin D: A d-lightful solution for health. *J. Investig. Med.* **2011**, *59*, 872–880. [[CrossRef](#)]
10. Heaney, R.P.; Armas, L.A.G.; French, C. All-Source Basal Vitamin D Inputs Are Greater Than Previously Thought and Cutaneous Inputs Are Smaller. *J. Nutr.* **2013**, *143*, 571–575. [[CrossRef](#)]
11. Barrea, L.; Savastano, S.; Di Somma, C.; Savanelli, M.C.; Nappi, F.; Albanese, L.; Orio, F.; Colao, A. Low serum vitamin D-status, air pollution and obesity: A dangerous liaison. *Rev. Endocr. Metab. Disord.* **2016**, *18*, 207–214. [[CrossRef](#)] [[PubMed](#)]
12. Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M.; Endocrine Society. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: An Endocrine Society Clinical Practice Guideline. *J. Clin. Endocrinol. Metab.* **2011**, *96*, 1911–1930. [[CrossRef](#)] [[PubMed](#)]
13. Schmid, A.; Walther, B. Natural Vitamin D Content in Animal Products. *Adv. Nutr.* **2013**, *4*, 453–462. [[CrossRef](#)]
14. Borel, P.; Caillaud, D.; Cano, N.J. Vitamin D Bioavailability: State of the Art. *Crit. Rev. Food Sci. Nutr.* **2013**, *55*, 1193–1205. [[CrossRef](#)]
15. Reboul, E. Intestinal absorption of vitamin D: From the meal to the enterocyte. *Food Funct.* **2014**, *6*, 356–362. [[CrossRef](#)] [[PubMed](#)]
16. Goncalves, A.; Roi, S.; Nowicki, M.; Dhaussy, A.; Huertas, A.; Amiot, M.J.; Reboul, E. Fat-soluble vitamin intestinal absorption: Absorption sites in the intestine and interactions for absorption. *Food Chem.* **2015**, *172*, 155–160. [[CrossRef](#)]
17. Hollander, D.; Muralidhara, K.S.; Zimmerman, A. Vitamin D-3 intestinal absorption in vivo: Influence of fatty acids, bile salts, and perfusate pH on absorption. *Gut* **1978**, *19*, 267–272. [[CrossRef](#)]
18. Reboul, E.; Goncalves, A.; Comera, C.; Bott, R.; Nowicki, M.; Landrier, J.-F.; Jourdeuil-Rahmani, D.; Dufour, C.; Collet, X.; Borel, P. Vitamin D intestinal absorption is not a simple passive diffusion: Evidences for involvement of cholesterol transporters. *Mol. Nutr. Food Res.* **2011**, *55*, 691–702. [[CrossRef](#)]
19. Margier, M.; Collet, X.; May, C.; Desmarchelier, C.; André, F.; Lebrun, C.; Defoort, C.; Bluteau, A.; Borel, P.; Lespine, A.; et al. ABCB1 (P-glycoprotein) regulates vitamin D absorption and contributes to its transintestinal efflux. *FASEB J.* **2018**, *33*, 2084–2094. [[CrossRef](#)]
20. Cheng, J.B.; Motola, D.L.; Mangelsdorf, D.J.; Russell, D.W. De-orphanization of cytochrome P450 2R1: A microsomal vitamin D 25-hydroxylase. *J. Biol. Chem.* **2003**, *278*, 38084–38093. [[CrossRef](#)]
21. Zhu, J.; DeLuca, H.F. Vitamin D 25-hydroxylase—Four decades of searching, are we there yet? *Arch. Biochem. Biophys.* **2012**, *523*, 30–36. [[CrossRef](#)] [[PubMed](#)]
22. Zhu, J.G.; Ochalek, J.T.; Kaufmann, M.; Jones, G.; DeLuca, H.F. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 15650–15655. [[CrossRef](#)] [[PubMed](#)]
23. Gupta, R.P.; Hollis, B.W.; Patel, S.B.; Patrick, K.S.; Bell, N.H. CYP3A4 is a Human Microsomal Vitamin D 25-Hydroxylase. *J. Bone Miner. Res.* **2003**, *19*, 680–688. [[CrossRef](#)] [[PubMed](#)]
24. Aiba, I.; Yamasaki, T.; Shinki, T.; Izumi, S.; Yamamoto, K.; Yamada, S.; Terato, H.; Ide, H.; Ohyama, Y. Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. *Steroids* **2006**, *71*, 849–856. [[CrossRef](#)]
25. Guo, Y.D.; Strugnell, S.; Back, D.W.; Jones, G. Transfected human liver cytochrome P-450 hydroxylates vitamin D analogs at different side-chain positions. *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 8668–8672. [[CrossRef](#)]
26. Bell, N.H.; Epstein, S.; Greene, A.; Shary, J.; Oexmann, M.J.; Shaw, S. Evidence for alteration of the vitamin D-endocrine system in obese subjects. *J. Clin. Investig.* **1985**, *76*, 370–373. [[CrossRef](#)]
27. Roizen, J.D.; Long, C.; Casella, A.; O’Lear, L.; Caplan, I.; Lai, M.; Sasson, I.; Singh, R.; Makowski, A.J.; Simmons, R.; et al. Obesity Decreases Hepatic 25-Hydroxylase Activity Causing Low Serum 25-Hydroxyvitamin D. *J. Bone Miner. Res.* **2019**, *34*, 1068–1073. [[CrossRef](#)]
28. Park, J.M.; Park, C.Y.; Han, S.N. High fat diet-Induced obesity alters vitamin D metabolizing enzyme expression in mice. *BioFactors* **2015**, *41*, 175–182. [[CrossRef](#)]
29. Bonnet, L.; Karkeni, E.; Couturier, C.; Astier, J.; Defoort, C.; Svilar, L.; Tourniaire, F.; Mounien, L.; Landrier, J.-F. Four days high fat diet modulates vitamin D metabolite levels and enzymes in mice. *J. Endocrinol.* **2021**, *248*, 87–93. [[CrossRef](#)]
30. Elkhwanky, M.; Kummu, O.; Piltonen, T.T.; Laru, J.; Morin-Papunen, L.; Mutikainen, M.; Tavi, P.; Hakkola, J. Obesity Represses CYP2R1, the Vitamin D 25-Hydroxylase, in the Liver and Extrahepatic Tissues. *JBMR Plus* **2020**, *4*. [[CrossRef](#)]
31. Aatsinki, S.-M.; Elkhwanky, M.-S.; Kummu, O.; Karpale, M.; Buler, M.; Viitala, P.; Rinne, V.; Mutikainen, M.; Tavi, P.; Franko, A.; et al. Fasting-Induced Transcription Factors Repress Vitamin D Bioactivation, a Mechanism for Vitamin D Deficiency in Diabetes. *Diabetes* **2019**, *68*, 918–931. [[CrossRef](#)] [[PubMed](#)]
32. Jones, K.S.; Schoenmakers, I.; Bluck, L.J.C.; Ding, S.; Prentice, A. Plasma appearance and disappearance of an oral dose of 25-hydroxyvitamin D<sub>2</sub> in healthy adults. *Br. J. Nutr.* **2011**, *107*, 1128–1137. [[CrossRef](#)]
33. Daiger, S.P.; Schanfield, M.S.; Cavalli-Sforza, L.L. Group-specific component (Gc) proteins bind vitamin D and 25-hydroxyvitamin D. *Proc. Natl. Acad. Sci. USA* **1975**, *72*, 2076–2080. [[CrossRef](#)] [[PubMed](#)]
34. Speeckaert, M.; Huang, G.; Delanghe, J.R.; Taes, Y.E.C. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. *Clin. Chim. Acta* **2006**, *372*, 33–42. [[CrossRef](#)] [[PubMed](#)]
35. Bouillon, R.; Schuit, F.; Antonio, L.; Rastinejad, F. Vitamin D Binding Protein: A Historic Overview. *Front. Endocrinol.* **2020**, *10*, 910. [[CrossRef](#)]



36. Haddad, J.G.; Jennings, A.S.; Aw, T.C. Vitamin D Uptake and Metabolism by Perfused Rat Liver: Influences of Carrier Proteins. *Endocrinology* **1988**, *123*, 498–504. [[CrossRef](#)]
37. Safadi, F.F.; Thornton, P.; Magiera, H.; Hollis, B.W.; Gentile, M.; Haddad, J.G.; Liebhaber, S.A.; Cooke, N.E. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. *J. Clin. Investig.* **1999**, *103*, 239–251. [[CrossRef](#)]
38. Nykjaer, A.; Dragun, D.; Walther, D.; Vorum, H.; Jacobsen, C.; Herz, J.; Melsen, F.; Christensen, E.I.; Willnow, T.E. An Endocytic Pathway Essential for Renal Uptake and Activation of the Steroid 25-(OH) Vitamin D<sub>3</sub>. *Cell* **1999**, *96*, 507–515. [[CrossRef](#)]
39. Dusso, A.S.; Brown, A.J.; Slatopolsky, E. Vitamin D. *Am. J. Physiol. Ren. Physiol.* **2005**, *289*, F8–F28. [[CrossRef](#)]
40. Kozyraki, R.; Cases, O. Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease. *Curr. Med. Chem.* **2020**, *27*, 3123–3150. [[CrossRef](#)]
41. Gacad, M.A.; Chen, H.; Arbelle, J.E.; LeBon, T.; Adams, J.S. Functional Characterization and Purification of an Intracellular Vitamin D-binding Protein in Vitamin D-resistant New World Primate Cells. *J. Biol. Chem.* **1997**, *272*, 8433–8440. [[CrossRef](#)] [[PubMed](#)]
42. Landrier, J.F.; Karkeni, E.; Marcotorchino, J.; Bonnet, L.; Tourniaire, F. Vitamin D modulates adipose tissue biology: Possible consequences for obesity? *Proc. Nutr. Soc.* **2016**, *75*, 38–46. [[CrossRef](#)] [[PubMed](#)]
43. Jones, G.; Prosser, D.E.; Kaufmann, M. Cytochrome P450-mediated metabolism of vitamin D. *J. Lipid Res.* **2014**, *55*, 13–31. [[CrossRef](#)]
44. Carlberg, C. Nutrigenomics of Vitamin D. *Nutrients* **2019**, *11*, 676. [[CrossRef](#)] [[PubMed](#)]
45. Slominski, A.T.; Tuoresmäki, P.; Väisänen, S.; Neme, A.; Heikkinen, S.; Carlberg, C. Patterns of Genome-Wide VDR Locations. *PLoS ONE* **2014**, *9*, e96105. [[CrossRef](#)]
46. Kazemian, E.; Amouzegar, A.; Akbari, M.E.; Moradi, N.; Gharibzadeh, S.; Jamshidi-Naeini, Y.; Khademolmele, M.; As'habi, A.; Davoodi, S.H. Vitamin D receptor gene polymorphisms affecting changes in visceral fat, waist circumference and lipid profile in breast cancer survivors supplemented with vitamin D<sub>3</sub>. *Lipids Health Dis.* **2019**, *18*, 161. [[CrossRef](#)]
47. Turano, C.; Gaucci, E.; Grillo, C.; Chichiarelli, S. ERp57/GRP58: A protein with multiple functions. *Cell. Mol. Biol. Lett.* **2011**, *16*, 539–563. [[CrossRef](#)]
48. Nemere, I.; Safford, S.E.; Rohe, B.; DeSouza, M.M.; Farach-Carson, M.C. Identification and characterization of 1,25D<sub>3</sub>-membrane-associated rapid response, steroid (1,25D<sub>3</sub>-MARRS) binding protein. *J. Steroid Biochem. Mol. Biol.* **2004**, *89–90*, 281–285. [[CrossRef](#)]
49. Chen, J.; Doroudi, M.; Cheung, J.; Grozier, A.L.; Schwartz, Z.; Boyan, B.D. Plasma membrane Pdia3 and VDR interact to elicit rapid responses to 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>. *Cell. Signal.* **2013**, *25*, 2362–2373. [[CrossRef](#)]
50. Zmijewski, M.A.; Carlberg, C. Vitamin D receptor(s): In the nucleus but also at membranes? *Exp. Dermatol.* **2020**, *29*, 876–884. [[CrossRef](#)]
51. Nemere, I.; Hintze, K. Novel hormone “receptors”. *J. Cell Biochem.* **2008**, *103*, 401–407. [[CrossRef](#)] [[PubMed](#)]
52. Ong, L.T.C.; Booth, D.R.; Parnell, G.P. Vitamin D and its Effects on DNA Methylation in Development, Aging, and Disease. *Mol. Nutr. Food Res.* **2020**, *64*, e2000437. [[CrossRef](#)] [[PubMed](#)]
53. Nur, S.M.; Rath, S.; Ahmad, V.; Ahmad, A.; Ateeq, B.; Khan, M.I. Nutritive vitamins as epidrugs. *Crit. Rev. Food Sci. Nutr.* **2020**, *61*, 1–13. [[CrossRef](#)] [[PubMed](#)]
54. Karkeni, E.; Bonnet, L.; Marcotorchino, J.; Tourniaire, F.; Astier, J.; Ye, J.; Landrier, J.-F. Vitamin D limits inflammation-linked microRNA expression in adipocytes *in vitro* and *in vivo*: A new mechanism for the regulation of inflammation by vitamin D. *Epigenetics* **2018**, *13*, 156–162. [[CrossRef](#)]
55. Bonnet, L.; Hachemi, M.A.; Karkeni, E.; Couturier, C.; Astier, J.; Defoort, C.; Svilar, L.; Martin, J.-C.; Tourniaire, F.; Landrier, J.-F. Diet induced obesity modifies vitamin D metabolism and adipose tissue storage in mice. *J. Steroid Biochem. Mol. Biol.* **2018**, *185*, 39–46. [[CrossRef](#)]
56. Seldeen, K.L.; Pang, M.; Rodriguez-Gonzalez, M.; Hernandez, M.; Sheridan, Z.; Yu, P.; Troen, B.R. A mouse model of vitamin D insufficiency: Is there a relationship between 25(OH) vitamin D levels and obesity? *Nutr. Metab.* **2017**, *14*, 26. [[CrossRef](#)]
57. Valle, M.; Mitchell, P.L.; Pilon, G.; St-Pierre, P.; Varin, T.; Richard, D.; Vohl, M.-C.; Jacques, H.; Delvin, E.; Levy, E.; et al. Cholecalciferol Supplementation Does Not Prevent the Development of Metabolic Syndrome or Enhance the Beneficial Effects of Omega-3 Fatty Acids in Obese Mice. *J. Nutr.* **2021**, *151*, 1175–1189. [[CrossRef](#)]
58. Marziou, A.; Philouze, C.; Couturier, C.; Astier, J.; Obert, P.; Landrier, J.-F.; Riva, C. Vitamin D Supplementation Improves Adipose Tissue Inflammation and Reduces Hepatic Steatosis in Obese C57BL/6J Mice. *Nutrients* **2020**, *12*, 342. [[CrossRef](#)]
59. Sergeev, I.N.; Song, Q. High vitamin D and calcium intakes reduce diet-induced obesity in mice by increasing adipose tissue apoptosis. *Mol. Nutr. Food Res.* **2014**, *58*, 1342–1348. [[CrossRef](#)]
60. Marcotorchino, J.; Tourniaire, F.; Astier, J.; Karkeni, E.; Canault, M.; Amiot, M.-J.; Bendahan, D.; Bernard, M.; Martin, J.-C.; Giannesini, B.; et al. Vitamin D protects against diet-induced obesity by enhancing fatty acid oxidation. *J. Nutr. Biochem.* **2014**, *25*, 1077–1083. [[CrossRef](#)]
61. Borges, C.C.; Salles, A.F.; Bringham, I.; Souza-Mello, V.; Mandarim-De-Lacerda, C.A.; Aguilá, M.B. Adverse effects of vitamin D deficiency on the Pi3k/Akt pathway and pancreatic islet morphology in diet-induced obese mice. *Mol. Nutr. Food Res.* **2015**, *60*, 346–357. [[CrossRef](#)] [[PubMed](#)]
62. Narvaez, C.J.; Matthews, D.; Broun, E.; Chan, M.; Welsh, J. Lean Phenotype and Resistance to Diet-Induced Obesity in Vitamin D Receptor Knockout Mice Correlates with Induction of Uncoupling Protein-1 in White Adipose Tissue. *Endocrinology* **2009**, *150*, 651–661. [[CrossRef](#)]



63. Wong, K.E.; Szeto, F.L.; Zhang, W.; Ye, H.; Kong, J.; Zhang, Z.; Sun, X.J.; Li, Y.C. Involvement of the vitamin D receptor in energy metabolism: Regulation of uncoupling proteins. *Am. J. Physiol. Metab.* **2009**, *296*, E820–E828. [[CrossRef](#)]
64. Weber, K.; Erben, R.G. Differences in triglyceride and cholesterol metabolism and resistance to obesity in male and female vitamin D receptor knockout mice. *J. Anim. Physiol. Anim. Nutr.* **2012**, *97*, 675–683. [[CrossRef](#)] [[PubMed](#)]
65. Bouillon, R.; Carmeliet, G.; Verlinden, L.; van Etten, E.; Verstuyf, A.; Luderer, H.F.; Lieben, L.; Mathieu, C.; DeMay, M. Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice. *Endocr. Rev.* **2008**, *29*, 726–776. [[CrossRef](#)] [[PubMed](#)]
66. Xu, Y.; Lou, Y.; Kong, J. VDR regulates energy metabolism by modulating remodeling in adipose tissue. *Eur. J. Pharmacol.* **2019**, *865*, 172761. [[CrossRef](#)] [[PubMed](#)]
67. Wong, K.E.; Kong, J.; Zhang, W.; Szeto, F.L.; Ye, H.; Deb, D.K.; Brady, M.J.; Li, Y.C. Targeted Expression of Human Vitamin D Receptor in Adipocytes Decreases Energy Expenditure and Induces Obesity in Mice. *J. Biol. Chem.* **2011**, *286*, 33804–33810. [[CrossRef](#)]
68. Matthews, D.G.; D'Angelo, J.; Drelich, J.; Welsh, J. Adipose-specific Vdr deletion alters body fat and enhances mammary epithelial density. *J. Steroid Biochem. Mol. Biol.* **2015**, *164*, 299–308. [[CrossRef](#)]
69. Tao, T.; Kobelski, M.M.; Saini, V.; Demay, M.B. Adipose-specific VDR Deletion Leads to Hepatic Steatosis in Female Mice Fed a Low-Fat Diet. *Endocrinology* **2021**, *163*. [[CrossRef](#)]
70. Lontchi-Yimagou, E.; Kang, S.; Goyal, A.; Zhang, K.; You, J.Y.; Carey, M.; Jain, S.; Bhansali, S.; Kehlenbrink, S.; Guo, P.; et al. Insulin-sensitizing effects of vitamin D repletion mediated by adipocyte vitamin D receptor: Studies in humans and mice. *Mol. Metab.* **2020**, *42*, 101095. [[CrossRef](#)]
71. Jahn, D.; Dorbath, D.; Kircher, S.; Nier, A.; Bergheim, I.; Lenaerts, K.; Hermanns, H.M.; Geier, A. Beneficial Effects of Vitamin D Treatment in an Obese Mouse Model of Non-Alcoholic Steatohepatitis. *Nutrients* **2019**, *11*, 77. [[CrossRef](#)] [[PubMed](#)]
72. Benetti, E.; Mastrocola, R.; Chiazza, F.; Nigro, D.; D'Antona, G.; Bordano, V.; Fantozzi, R.; Aragno, M.; Collino, M.; Minetto, M.A. Effects of vitamin D on insulin resistance and myosteosis in diet-induced obese mice. *PLoS ONE* **2018**, *13*, e0189707. [[CrossRef](#)] [[PubMed](#)]
73. Merino, O.; Gregorio, B.; Sampaio, F.; Sanchez, R.; Risopatrón, J. Role of Vitamin D in the Development of Obesity. *Int. J. Morphol.* **2017**, *35*, 1568–1575. [[CrossRef](#)]
74. Fan, Y.; Futawaka, K.; Koyama, R.; Fukuda, Y.; Hayashi, M.; Imamoto, M.; Miyawaki, T.; Kasahara, M.; Tagami, T.; Moriyama, K. Vitamin D<sub>3</sub>/VDR resists diet-induced obesity by modulating UCP3 expression in muscles. *J. Biomed. Sci.* **2016**, *23*, 56. [[CrossRef](#)]
75. Aldekwer, S.; Desiderio, A.; Farges, M.-C.; Rougé, S.; Le Naour, A.; Le Guennec, D.; Goncalves-Mendès, N.; Mille-Hamard, L.; Momken, I.; Rossary, A.; et al. Vitamin D supplementation associated with physical exercise promotes a tolerogenic immune environment without effect on mammary tumour growth in C57BL/6 mice. *Eur. J. Nutr.* **2021**, *60*, 2521–2535. [[CrossRef](#)]
76. Li, R.; Guo, E.; Yang, J.; Li, A.; Yang, Y.; Liu, S.; Liu, A.; Jiang, X. 1,25(OH)<sub>2</sub>D<sub>3</sub> attenuates hepatic steatosis by inducing autophagy in mice. *Obesity* **2017**, *25*, 561–571. [[CrossRef](#)]
77. Geldenhuys, S.; Hart, P.H.; Endersby, R.; Jacoby, P.; Feelisch, M.; Weller, R.B.; Matthews, V.; Gorman, S. Ultraviolet Radiation Suppresses Obesity and Symptoms of Metabolic Syndrome Independently of Vitamin D in Mice Fed a High-Fat Diet. *Diabetes* **2014**, *63*, 3759–3769. [[CrossRef](#)]
78. Guareschi, Z.M.; Valcanaia, A.C.; Ceglarek, V.M.; Hotz, P.; Amaral, B.K.; de Souza, D.W.; de Souza, T.A.; Nardelli, T.; Ferreira, T.R.; Leite, N.C.; et al. The effect of chronic oral vitamin D supplementation on adiposity and insulin secretion in hypothalamic obese rats. *Br. J. Nutr.* **2019**, *121*, 1334–1344. [[CrossRef](#)]
79. Park, C.Y.; Kim, T.Y.; Yoo, J.S.; Seo, Y.; Pae, M.; Han, S.N. Effects of 1,25-Dihydroxyvitamin D<sub>3</sub> on the Inflammatory Responses of Stromal Vascular Cells and Adipocytes from Lean and Obese Mice. *Nutrients* **2020**, *12*, 364. [[CrossRef](#)]
80. Liu, X.-J.; Wang, B.-W.; Zhang, C.; Xia, M.-Z.; Chen, Y.-H.; Hu, C.-Q.; Wang, H.; Chen, X.; Xu, D.-X. Vitamin D Deficiency Attenuates High-Fat Diet-Induced Hyperinsulinemia and Hepatic Lipid Accumulation in Male Mice. *Endocrinology* **2015**, *156*, 2103–2113. [[CrossRef](#)]
81. Bastie, C.C.; Gaffney-Stomberg, E.; Lee, T.-W.A.; Dhima, E.; Pessin, J.E.; Augenlicht, L.H. Dietary Cholecalciferol and Calcium Levels in a Western-Style Defined Rodent Diet Alter Energy Metabolism and Inflammatory Responses in Mice. *J. Nutr.* **2012**, *142*, 859–865. [[CrossRef](#)] [[PubMed](#)]
82. Bhat, M.; Noolu, B.; Qadri, S.S.; Ismail, A. Vitamin D deficiency decreases adiposity in rats and causes altered expression of uncoupling proteins and steroid receptor coactivator3. *J. Steroid Biochem. Mol. Biol.* **2014**, *144*, 304–312. [[CrossRef](#)] [[PubMed](#)]
83. Fleet, J.C.; Gliniak, C.; Zhang, Z.; Xue, Y.; Smith, K.B.; McCreedy, R.; Adedokun, S.A. Serum Metabolite Profiles and Target Tissue Gene Expression Define the Effect of Cholecalciferol Intake on Calcium Metabolism in Rats and Mice. *J. Nutr.* **2008**, *138*, 1114–1120. [[CrossRef](#)] [[PubMed](#)]
84. Bonnet, L.; Karkeni, E.; Couturier, C.; Astier, J.; Dalifard, J.; Defoort, C.; Svilar, L.; Martin, J.-C.; Tourniaire, F.; Landrier, J.-F. Gene Expression Pattern in Response to Cholecalciferol Supplementation Highlights Cubilin as a Major Protein of 25(OH)D Uptake in Adipocytes and Male Mice White Adipose Tissue. *Endocrinology* **2017**, *159*, 957–966. [[CrossRef](#)] [[PubMed](#)]
85. Walsh, J.S.; Evans, A.L.; Bowles, S.; Naylor, K.E.; Jones, K.S.; Schoenmakers, I.; Jacques, R.M.; Eastell, R. Free 25-hydroxyvitamin D is low in obesity, but there are no adverse associations with bone health. *Am. J. Clin. Nutr.* **2016**, *103*, 1465–1471. [[CrossRef](#)]
86. Soares, M.J.; Murhadi, L.L.; Kurpad, A.V.; Ping-Delfos, W.L.C.S.; Piers, L.S. Mechanistic roles for calcium and vitamin D in the regulation of body weight. *Obes. Rev.* **2012**, *13*, 592–605. [[CrossRef](#)]

87. Schutkowski, A.; Max, D.; Bönn, M.; Brandsch, C.; Grundmann, S.M.; Hirche, F.; Staeger, M.S.; Stangl, G.I. Vitamin D Does Not Play a Functional Role in Adipose Tissue Development in Rodent Models. *Mol. Nutr. Food Res.* **2018**, *62*, 1700726. [[CrossRef](#)]
88. Chang, E.; Kim, Y. Vitamin D Insufficiency Exacerbates Adipose Tissue Macrophage Infiltration and Decreases AMPK/SIRT1 Activity in Obese Rats. *Nutrients* **2017**, *9*, 338. [[CrossRef](#)]
89. Chanet, A.; Salles, J.; Guillet, C.; Giraudet, C.; Berry, A.; Patrac, V.; Domingues-Faria, C.; Tagliaferri, C.; Bouton, K.; Bertrand-Michel, J.; et al. Vitamin D supplementation restores the blunted muscle protein synthesis response in deficient old rats through an impact on ectopic fat deposition. *J. Nutr. Biochem.* **2017**, *46*, 30–38. [[CrossRef](#)]
90. Domingues-Faria, C.; Chanet, A.; Salles, J.; Berry, A.; Giraudet, C.; Patrac, V.; Denis, P.; Bouton, K.; Goncalves-Mendes, N.; Vasson, M.-P.; et al. Vitamin D deficiency down-regulates Notch pathway contributing to skeletal muscle atrophy in old wistar rats. *Nutr. Metab.* **2014**, *11*, 47. [[CrossRef](#)]
91. Peng, X.; Shang, G.; Wang, W.; Chen, X.; Lou, Q.; Zhai, G.; Li, D.; Du, Z.; Ye, Y.; Jin, X.; et al. Fatty Acid Oxidation in Zebrafish Adipose Tissue Is Promoted by  $1\alpha,25(\text{OH})_2\text{D}_3$ . *Cell Reports* **2017**, *19*, 1444–1455. [[CrossRef](#)] [[PubMed](#)]
92. Knuth, M.M.; Mahapatra, D.; Jima, D.; Wan, D.; Hammock, B.D.; Law, M.; Kullman, S.W. Vitamin D deficiency serves as a precursor to stunted growth and central adiposity in zebrafish. *Sci. Rep.* **2020**, *10*, 1–13. [[CrossRef](#)] [[PubMed](#)]
93. Barrea, L.; Muscogiuri, G.; Laudisio, D.; Pugliese, G.; De Alteriis, G.; Colao, A.; Savastano, S. Influence of the Mediterranean Diet on 25-Hydroxyvitamin D Levels in Adults. *Nutrients* **2020**, *12*, 1439. [[CrossRef](#)] [[PubMed](#)]
94. Hyppönen, E.; Boucher, B.J. Adiposity, vitamin D requirements, and clinical implications for obesity-related metabolic abnormalities. *Nutr. Rev.* **2018**, *76*, 678–692. [[CrossRef](#)]
95. Marquina, C.; Mousa, A.; Scragg, R.; De Courten, B. Vitamin D and cardiometabolic disorders: A review of current evidence, genetic determinants and pathomechanisms. *Obes. Rev.* **2018**, *20*, 262–277. [[CrossRef](#)]
96. Cheng, S.; Massaro, J.M.; Fox, C.S.; Larson, M.G.; Keyes, M.J.; McCabe, E.L.; Robins, S.J.; O'Donnell, C.J.; Hoffmann, U.; Jacques, P.F.; et al. Adiposity, Cardiometabolic Risk, and Vitamin D Status: The Framingham Heart Study. *Diabetes* **2009**, *59*, 242–248. [[CrossRef](#)]
97. McGill, A.-T.; Stewart, J.M.; Lithander, F.E.; Strik, C.M.; Poppitt, S.D. Relationships of low serum vitamin D<sub>3</sub> with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. *Nutr. J.* **2008**, *7*, 4. [[CrossRef](#)]
98. Fu, Z.; Xu, C.; Shu, Y.; Xie, Z.; Lu, C.; Mo, X. Serum 25-hydroxyvitamin D is associated with obesity and metabolic parameters in US children. *Public Health Nutr.* **2019**, *23*, 1214–1222. [[CrossRef](#)]
99. Perna, S. The enigma of vitamin D supplementation in aging with obesity. *Minerva Gastroenterol.* **2021**. [[CrossRef](#)]
100. Parikh, S.J.; Edelman, M.; Uwaifo, G.I.; Freedman, R.J.; Semega-Janneh, M.; Reynolds, J.; Yanovski, J. The Relationship between Obesity and Serum 1,25-Dihydroxy Vitamin D Concentrations in Healthy Adults. *J. Clin. Endocrinol. Metab.* **2004**, *89*, 1196–1199. [[CrossRef](#)]
101. Konradsen, S.; Ag, H.; Lindberg, F.; Hexeberg, S.; Jorde, R. Serum 1,25-dihydroxy vitamin D is inversely associated with body mass index. *Eur. J. Nutr.* **2008**, *47*, 87–91. [[CrossRef](#)] [[PubMed](#)]
102. Pramono, A.; Jocken, J.W.E.; Goossens, G.H.; Blaak, E.E. Vitamin D release across abdominal adipose tissue in lean and obese men: The effect of  $\beta$ -adrenergic stimulation. *Physiol. Rep.* **2019**, *7*, e14308. [[CrossRef](#)] [[PubMed](#)]
103. Wortsman, J.; Matsuoka, L.Y.; Chen, T.C.; Lu, Z.; Holick, M.F. Decreased bioavailability of vitamin D in obesity. *Am. J. Clin. Nutr.* **2000**, *72*, 690–693. [[CrossRef](#)]
104. Drincic, A.T.; Armas, L.A.; Van Diest, E.E.; Heaney, R.P. Volumetric Dilution, Rather Than Sequestration Best Explains the Low Vitamin D Status of Obesity. *Obesity* **2012**, *20*, 1444–1448. [[CrossRef](#)] [[PubMed](#)]
105. Wamberg, L.; Christiansen, T.; Paulsen, S.K.; Fisker, S.; Rask, P.; Rejnmark, L.; Richelsen, B.; Pedersen, S.B. Expression of vitamin D-metabolizing enzymes in human adipose tissue—the effect of obesity and diet-induced weight loss. *Int. J. Obes.* **2012**, *37*, 651–657. [[CrossRef](#)] [[PubMed](#)]
106. de Oliveira, L.F.; de Azevedo, L.G.; da Mota Santana, J.; de Sales, L.P.C.; Pereira-Santos, M. Obesity and overweight decreases the effect of vitamin D supplementation in adults: Systematic review and meta-analysis of randomized controlled trials. *Rev. Endocr. Metab. Disord.* **2019**, *21*, 67–76. [[CrossRef](#)] [[PubMed](#)]
107. Gilbert-Diamond, D.; Baylin, A.; Mora, M.; Marin, C.; Arsenault, J.E.; Hughes, M.D.; Willett, W.C.; Villamor, E. Vitamin D deficiency and anthropometric indicators of adiposity in school-age children: A prospective study. *Am. J. Clin. Nutr.* **2010**, *92*, 1446–1451. [[CrossRef](#)]
108. Mai, X.-M.; Chen, Y.; Camargo, C.A.; Langhammer, A. Cross-Sectional and Prospective Cohort Study of Serum 25-Hydroxyvitamin D Level and Obesity in Adults: The HUNT Study. *Am. J. Epidemiol.* **2012**, *175*, 1029–1036. [[CrossRef](#)]
109. González-Molero, I.; Rojo-Martínez, G.; Morcillo, S.; Gutierrez, C.; Rubio, E.; Pérez-Valero, V.; Esteva, I.; De Adana, M.S.R.; Almaraz, M.C.; Colomo, N.; et al. Hypovitaminosis D and incidence of obesity: A prospective study. *Eur. J. Clin. Nutr.* **2013**, *67*, 680–682. [[CrossRef](#)] [[PubMed](#)]
110. LeBlanc, E.S.; Rizzo, J.H.; Pedula, K.L.; Ensrud, K.E.; Cauley, J.; Hochberg, M. Associations Between 25-Hydroxyvitamin D and Weight Gain in Elderly Women. *J. Women's Health* **2012**, *21*, 1066–1073. [[CrossRef](#)]
111. Gagnon, C.; Lu, Z.X.; Magliano, D.J.; Dunstan, D.W.; Shaw, J.E.; Zimmet, P.Z.; Sikaris, K.; Ebeling, P.R.; Daly, R.M. Low Serum 25-Hydroxyvitamin D Is Associated with Increased Risk of the Development of the Metabolic Syndrome at Five Years: Results from a National, Population-Based Prospective Study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab). *J. Clin. Endocrinol. Metab.* **2012**, *97*, 1953–1961. [[CrossRef](#)] [[PubMed](#)]

112. Kamycheva, E.; Joakimsen, R.M.; Jorde, R. Intakes of Calcium and Vitamin D Predict Body Mass Index in the Population of Northern Norway. *J. Nutr.* **2003**, *133*, 102–106. [[CrossRef](#)] [[PubMed](#)]
113. Ochs-Balcom, H.M.; Chennamaneni, R.; Millen, A.E.; Shields, P.G.; Marian, C.; Trevisan, M.; Freudenheim, J.L. Vitamin D receptor gene polymorphisms are associated with adiposity phenotypes. *Am. J. Clin. Nutr.* **2010**, *93*, 5–10. [[CrossRef](#)] [[PubMed](#)]
114. Bienertová-Vašků, J.; Zlámal, F.; Pohorálá, A.; Mikeš, O.; Goldbergová-Pávková, M.; Novák, J.; Šplíchal, Z.; Pikhart, H. Allelic variants in vitamin D receptor gene are associated with adiposity measures in the central-European population. *BMC Med. Genet.* **2017**, *18*, 1–9. [[CrossRef](#)]
115. Ye, W.Z.; Reis, A.F.; Dubois-Laforgue, D.; Bellanné-Chantelot, C.; Timsit, J.; Velho, G. Vitamin D receptor gene polymorphisms are associated with obesity in type 2 diabetic subjects with early age of onset. *Eur. J. Endocrinol.* **2001**, *145*, 181–186. [[CrossRef](#)]
116. Xu, H.; Xiong, D.-H.; Xu, F.-H.; Zhang, Y.-Y.; Lei, S.-F.; Deng, H.-W. Association between VDR ApaI Polymorphism and Hip Bone Mineral Density Can Be Modified by Body Mass Index: A Study on Postmenopausal Chinese Women. *Acta Biochim. Biophys. Sin.* **2005**, *37*, 61–67. [[CrossRef](#)]
117. Jiang, H.; Xiong, D.-H.; Guo, Y.-F.; Shen, H.; Xiao, P.; Yang, F.; Chen, Y.; Zhang, F.; Recker, R.R.; Deng, H.-W. Association analysis of vitamin D-binding protein gene polymorphisms with variations of obesity-related traits in Caucasian nuclear families. *Int. J. Obes.* **2007**, *31*, 1319–1324. [[CrossRef](#)]
118. Vimalaewaran, K.S.; The Genetic Investigation of Anthropometric Traits (GIANT) Consortium; Cavadino, A.; Berry, D.J.; Whittaker, J.; Power, C.; Jarvelin, M.-R.; Hypponen, E. Genetic association analysis of vitamin D pathway with obesity traits. *Int. J. Obes.* **2013**, *37*, 1399–1406. [[CrossRef](#)]
119. Dorjgochoo, T.; Shi, J.; Gao, Y.-T.; Long, J.; Delahanty, R.; Xiang, Y.-B.; Cai, Q.; Shu, X.O. Genetic variants in vitamin D metabolism-related genes and body mass index: Analysis of genome-wide scan data of approximately 7000 Chinese women. *Int. J. Obes.* **2011**, *36*, 1252–1255. [[CrossRef](#)]
120. Vimalaewaran, K.S.; Berry, D.J.; Lu, C.; Tikkanen, E.; Pilz, S.; Hiraki, L.T.; Cooper, J.D.; Dastani, Z.; Li, R.; Houston, D.K.; et al. Causal Relationship between Obesity and Vitamin D Status: Bi-Directional Mendelian Randomization Analysis of Multiple Cohorts. *PLoS Med.* **2013**, *10*, e1001383. [[CrossRef](#)]
121. Mallard, S.R.; Howe, A.S.; Houghton, L.A. Vitamin D status and weight loss: A systematic review and meta-analysis of randomized and nonrandomized controlled weight-loss trials. *Am. J. Clin. Nutr.* **2016**, *104*, 1151–1159. [[CrossRef](#)] [[PubMed](#)]
122. Pannu, P.K.; Zhao, Y.; Soares, M.J. Reductions in body weight and percent fat mass increase the vitamin D status of obese subjects: A systematic review and meta-regression analysis. *Nutr. Res.* **2015**, *36*, 201–213. [[CrossRef](#)] [[PubMed](#)]
123. Pathak, K.; Soares, M.J.; Calton, E.K.; Zhao, Y.; Hallett, J. Vitamin D supplementation and body weight status: A systematic review and meta-analysis of randomized controlled trials. *Obes. Rev.* **2014**, *15*, 528–537. [[CrossRef](#)] [[PubMed](#)]
124. Golzarand, M.; Hollis, B.W.; Mirmiran, P.; Wagner, C.L.; Shab-Bidar, S. Vitamin D supplementation and body fat mass: A systematic review and meta-analysis. *Eur. J. Clin. Nutr.* **2018**, *72*, 1345–1357. [[CrossRef](#)]
125. Perna, S. Is Vitamin D Supplementation Useful for Weight Loss Programs? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Medicina* **2019**, *55*, 368. [[CrossRef](#)]
126. Boucher, B.J. Why do so many trials of vitamin D supplementation fail? *Endocr. Connect.* **2020**, *9*, R195–R206. [[CrossRef](#)]
127. Shin, J.; Choi, M.; Longtine, M.; Nelson, D. Vitamin D effects on pregnancy and the placenta. *Placenta* **2010**, *31*, 1027–1034. [[CrossRef](#)]
128. Olmos-Ortiz, A.; Avila, E.; Durand-Carbajal, M.; Díaz, L. Regulation of Calcitriol Biosynthesis and Activity: Focus on Gestational Vitamin D Deficiency and Adverse Pregnancy Outcomes. *Nutrients* **2015**, *7*, 443–480. [[CrossRef](#)]
129. Larqué, E.; Morales, E.; Leis, R.; Blanco-Carnero, J.E. Maternal and Foetal Health Implications of Vitamin D Status during Pregnancy. *Ann. Nutr. Metab.* **2018**, *72*, 179–192. [[CrossRef](#)]
130. Ideraabdullah, F.Y.; Belenchia, A.M.; Rosenfeld, C.S.; Kullman, S.W.; Knuth, M.; Mahapatra, D.; Bereman, M.; Levin, E.D.; Peterson, C.A. Maternal vitamin D deficiency and developmental origins of health and disease (DOHaD). *J. Endocrinol.* **2019**, *241*, R65–R80. [[CrossRef](#)]
131. Miliku, K.; Vinkhuyzen, A.; Blanken, L.M.E.; McGrath, J.; Eyles, D.; Burne, T.; Hofman, A.; Tiemeier, H.; Steegers, E.A.; Gaillard, R.; et al. Maternal vitamin D concentrations during pregnancy, fetal growth patterns, and risks of adverse birth outcomes. *Am. J. Clin. Nutr.* **2016**, *103*, 1514–1522. [[CrossRef](#)] [[PubMed](#)]
132. Achkar, M.; Dodds, L.; Giguère, Y.; Forest, J.-C.; Armson, B.A.; Woolcott, C.; Agellon, S.; Spencer, A.; Weiler, H.A. Vitamin D status in early pregnancy and risk of preeclampsia. *Am. J. Obstet. Gynecol.* **2014**, *212*, 511.e1–511.e7. [[CrossRef](#)] [[PubMed](#)]
133. Amraei, M.; Mohamadpour, S.; Sayehmiri, K.; Mousavi, S.F.; Shirzadpour, E.; Moayeri, A. Effects of Vitamin D Deficiency on Incidence Risk of Gestational Diabetes Mellitus: A Systematic Review and Meta-analysis. *Front. Endocrinol.* **2018**, *9*, 7. [[CrossRef](#)] [[PubMed](#)]
134. Gernand, A.D.; Simhan, H.N.; Klebanoff, M.A.; Bodnar, L.M. Maternal Serum 25-Hydroxyvitamin D and Measures of Newborn and Placental Weight in a U.S. Multicenter Cohort Study. *J. Clin. Endocrinol. Metab.* **2013**, *98*, 398–404. [[CrossRef](#)]
135. Wang, H.; Xiao, Y.; Zhang, L.; Gao, Q. Maternal early pregnancy vitamin D status in relation to low birth weight and small-for-gestational-age offspring. *J. Steroid Biochem. Mol. Biol.* **2018**, *175*, 146–150. [[CrossRef](#)]
136. Reichetzedder, C.; Chen, H.; Föller, M.; Slowinski, T.; Li, J.; Chen, Y.-P.; Lang, F.; Hochoer, B. Maternal Vitamin D Deficiency and Fetal Programming—Lessons Learned from Humans and Mice. *Kidney Blood Press. Res.* **2014**, *39*, 315–329. [[CrossRef](#)]

137. Bodnar, L.M.; Catov, J.M.; Zmuda, J.M.; Cooper, M.E.; Parrott, M.S.; Roberts, J.M.; Marazita, M.L.; Simhan, H.N. Maternal Serum 25-Hydroxyvitamin D Concentrations Are Associated with Small-for-Gestational Age Births in White Women. *J. Nutr.* **2010**, *140*, 999–1006. [[CrossRef](#)]
138. Crozier, S.R.; Harvey, N.C.; Inskip, H.M.; Godfrey, K.M.; Cooper, C.; Robinson, S.M. Maternal vitamin D status in pregnancy is associated with adiposity in the offspring: Findings from the Southampton Women’s Survey. *Am. J. Clin. Nutr.* **2012**, *96*, 57–63. [[CrossRef](#)]
139. Boyle, V.T.; Thorstensen, E.B.; Thompson, J.M.D.; McCowan, L.M.E.; A Mitchell, E.; Godfrey, K.M.; Poston, L.; Wall, C.R.; Murphy, R.; Cutfield, W.; et al. The relationship between maternal 25-hydroxyvitamin D status in pregnancy and childhood adiposity and allergy: An observational study. *Int. J. Obes.* **2017**, *41*, 1755–1760. [[CrossRef](#)]
140. Miliku, K.; Felix, J.F.; Voortman, T.; Tiemeier, H.; Eyles, D.; Burne, T.; McGrath, J.; Jaddoe, V.W. Associations of maternal and fetal vitamin D status with childhood body composition and cardiovascular risk factors. *Matern. Child Nutr.* **2018**, *15*, e12672. [[CrossRef](#)]
141. Krishnaveni, G.V.; Veena, S.R.; Winder, N.R.; Hill, J.C.; Noonan, K.; Boucher, B.J.; Karat, S.C.; Fall, C.H. Maternal vitamin D status during pregnancy and body composition and cardiovascular risk markers in Indian children: The Mysore Parthenon Study. *Am. J. Clin. Nutr.* **2011**, *93*, 628–635. [[CrossRef](#)] [[PubMed](#)]
142. Tint, M.T.; Chong, M.F.; Aris, I.; Godfrey, K.M.; Quah, P.L.; Kapur, J.; Saw, S.M.; Gluckman, P.D.; Rajadurai, V.S.; Yap, F.; et al. Association between maternal mid-gestation vitamin D status and neonatal abdominal adiposity. *Int. J. Obes.* **2018**, *42*, 1296–1305. [[CrossRef](#)] [[PubMed](#)]
143. Daraki, V.; Roumeliotaki, T.; Chalkiadaki, G.; Katrinaki, M.; Karachaliou, M.; Leventakou, V.; Vafeiadi, M.; Sarri, K.; Vassilaki, M.; Papavasiliou, S.; et al. Low maternal vitamin D status in pregnancy increases the risk of childhood obesity. *Pediatr. Obes.* **2018**, *13*, 467–475. [[CrossRef](#)] [[PubMed](#)]
144. Morales, E.; Rodriguez, A.; Valvi, D.; Iñiguez, C.; Esplugues, A.; Vioque, J.; Marina, L.S.; Jiménez, A.; Espada, M.; Dehli, C.R.; et al. Deficit of vitamin D in pregnancy and growth and overweight in the offspring. *Int. J. Obes.* **2014**, *39*, 61–68. [[CrossRef](#)] [[PubMed](#)]
145. Rytter, D.; Bech, B.H.; Halldorsson, T.; Henriksen, T.B.; Grandström, C.; Cohen, A.; Olsen, S. Maternal Vitamin D Status at Week 30 of Gestation and Offspring Cardio-Metabolic Health at 20 Years: A Prospective Cohort Study over Two Decades. *PLoS ONE* **2016**, *11*, e0164758. [[CrossRef](#)] [[PubMed](#)]
146. Palacios, C.; Kostiuik, L.K.; Peña-Rosas, J.P. Vitamin D supplementation for women during pregnancy. *Cochrane Database Syst. Rev.* **2019**, *26*, 7. [[CrossRef](#)] [[PubMed](#)]
147. Ma, K.; Wei, S.; Bi, W.; Weiler, H.; Wen, S. Effect of Vitamin D Supplementation in Early Life on Children’s Growth and Body Composition: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Nutrients* **2021**, *13*, 524. [[CrossRef](#)]
148. Wen, J.; Hong, Q.; Wang, X.; Zhu, L.; Wu, T.; Xu, P.; Fu, Z.; You, L.; Wang, X.; Ji, C.; et al. The effect of maternal vitamin D deficiency during pregnancy on body fat and adipogenesis in rat offspring. *Sci. Rep.* **2018**, *8*, 1–8. [[CrossRef](#)]
149. Nascimento, F.A.M.; Ceciliano, T.C.; Aguila, M.B.; Mandarin-De-Lacerda, C. Transgenerational Effects on the Liver and Pancreas Resulting from Maternal Vitamin D Restriction in Mice. *J. Nutr. Sci. Vitaminol.* **2013**, *59*, 367–374. [[CrossRef](#)]
150. Xue, J.; Schoenrock, S.A.; Valdar, W.; Tarantino, L.M.; Ideraabdullah, F.Y. Maternal vitamin D depletion alters DNA methylation at imprinted loci in multiple generations. *Clin. Epigenet.* **2016**, *8*, 107. [[CrossRef](#)]
151. Zhang, H.; Chu, X.; Huang, Y.; Li, G.; Wang, Y.; Li, Y.; Sun, C. Maternal vitamin D deficiency during pregnancy results in insulin resistance in rat offspring, which is associated with inflammation and *Ikbx* methylation. *Diabetologia* **2014**, *57*, 2165–2172. [[CrossRef](#)] [[PubMed](#)]
152. Belenchia, A.M.; Johnson, S.A.; Ellersieck, M.R.; Rosenfeld, C.S.; A Peterson, C. In utero vitamin D deficiency predisposes offspring to long-term adverse adipose tissue effects. *J. Endocrinol.* **2017**, *234*, 301–313. [[CrossRef](#)] [[PubMed](#)]
153. Seipelt, E.M.; Tourniaire, F.; Couturier, C.; Astier, J.; Loriod, B.; Vachon, H.; Pucéat, M.; Mounien, L.; Landrier, J. Prenatal maternal vitamin D deficiency sex-dependently programs adipose tissue metabolism and energy homeostasis in offspring. *FASEB J.* **2020**, *34*, 14905–14919. [[CrossRef](#)] [[PubMed](#)]
154. Heaney, R.P. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. *Nutr. Rev.* **2013**, *72*, 48–54. [[CrossRef](#)]